OX390

OX390 is an investigational small molecule new chemical entity (NCE) being developed by Orexo in partnership with the Biomedical Advanced Research and Development Authority (BARDA). It is designed as a rescue medication to reverse respiratory depression associated with illicit opioid overdoses, specifically those involving opioids adulterated with alpha-2 adrenergic agonists such as xylazine or medetomidine. The drug utilizes Orexo's proprietary AmorphOX® dry-powder technology for intranasal delivery, which is intended to provide rapid drug exposure and high stability. OX390 is intended for community-based use by first responders and laypersons to address the growing public health crisis of adulterated fentanyl overdoses, often referred to as 'tranq' overdoses.